US Unemployment Looms As A Threat To Pharma, But More Impact In 2021
Sweeping job losses in the US have left people uninsured or transitioning from private insurance to Medicaid, which will impact how drugs are reimbursed. Changing payer mix will have an effect on company revenues.
You may also be interested in...
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.